Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.

International journal of oncology - 1 Feb 2015

Ofuji Kazuya, Tada Yoshitaka, Yoshikawa Toshiaki, Shimomura Manami, Yoshimura Mayuko, Saito Keigo, Nakamoto Yasunari, Nakatsura Tetsuya

Abstract excerpt

Lung cancer is the leading cause of cancer‑related deaths worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. However, in most cases, patients develop acquired resistance to EGFR‑TKI therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Peptides

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 25532027
DOI: 10.3892/ijo.2014.2787
PMCID: PMC4277252

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.PMID 25532027Read ↗

EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.Semantic proximity Read ↗

Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.Semantic proximity Read ↗

Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients.Semantic proximity Read ↗

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.Semantic proximity Read ↗

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.Semantic proximity Read ↗

Non metastasis protein 2 (NME2) is a potential target for leukemia-specific immunotherapySemantic proximity Read ↗

Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99.Semantic proximity Read ↗

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Semantic proximity Read ↗

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.Semantic proximity Read ↗

T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.Semantic proximity Read ↗

Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.Semantic proximity Read ↗

Identification of human telomerase reverse transcriptase–derived peptides that induce HLA-A24–restricted antileukemia cytotoxic T lymphocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.